NVS  Novartis Ag




Consumer Durables


Major Pharmaceuticals

Market Cap.


Vuru Grade


Current Price

+1.61 (+1.89%)

Growth Price

Overvalued by 21.84%

Stability Price

Overvalued by 71.56%

Company Metrics

  • 21.59 P/E
  • 3.48 P/S
  • 2.93 P/B
  • 3.938 EPS
  • 13.46% Cash ROIC
  • 0.35 Cash Ratio
  • 2.719 / 3.2% Dividend
  • 1.34M Avg. Vol.
  • 210.2B Market Cap.

Company Description

Novartis AG, through its subsidiaries, engages in the research, development, manufacture, and marketing of healthcare products worldwide. Its Pharmaceuticals division offers prescription medicines in various therapeutic areas, including cardiovascular and metabolism; oncology; neuroscience and ophthalmics; respiratory; integrated hospital care; and other additional products. The company's Vaccines...

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Stocks Alert: Novartis AG (ADR) (NYSE:NVS), Chimerix Inc (NASDAQ:CMRX ...
Street Newswire - Oct 8, 2014
Novartis AG (ADR) (NYSE:NVS) said three members of its executive committee will leave the health-care company following the completion of the sales of its animal health, OTC drugs, and vaccine units to Eli Lilly (LLY) and GlaxoSmithKline (GSK).
Eye Catching Stocks: EXCO Resources Inc (NYSE:XCO), Novartis AG (ADR ...
StreetWise Report - Oct 13, 2014
Novartis AG (ADR) (NYSE:NVS) presents data at EADV showing reliable efficiency of AIN457 in clearing skin of psoriasis patients (NVS) : new investigation of AIN457 (secukinumab) Phase III studies explains that treatment with secukinumab 300 mg resulted ...
Pharma Stocks To Look Out For This Week
Bidness ETC - Oct 13, 2014
The US Food and Drug Administration (FDA) is also expected to release briefs for the Advisory Committee's meeting next week to give recommendations on Novartis AG (ADR)'s (NVS) secukinumab and Vertex Pharmaceuticals Incorporated's (VRTX) ...
Novartis's Signifor Closer To EU Approval
Bidness ETC - Sep 28, 2014
Novartis's Signifor is capable of treating acromegaly in adults, who are unable to go through a surgery as an alternative option, and those on whom first-generation somatostatin analogues (SSAs), including Novartis's Sandostatin LAR, have not worked ...
Novartis Releases Positive Phase 3 Results For Psoriatic Arthritis Drug
Bidness ETC - Sep 25, 2014
Novartis AG (ADR) (NVS) today released top line results for two late-stage pivotal studies, which evaluated its novel drug secukinumab as a treatment for psoriatic arthritis (PsA).
Pharma Stock Updates - Pfizer Inc. (NYSE:PFE), Novartis AG (ADR) (NYSE:NVS ...
Equities Focus (registration) - Sep 25, 2014
Novartis AG (ADR) (NYSE:NVS) said late on Wednesday that its experimental drug secukinumab worker better than a placebo in two pivotal Phase III studies on psoriatic arthritis, a long-lasting condition that causes joint pain and stiffness and which ...
Drug maker's Trio: AstraZeneca plc (ADR) (NYSE:AZN), Novartis AG (ADR ...
StreetWise Report - Oct 14, 2014
Swiss drugmaker Novartis AG (ADR) (NYSE:NVS) said three members of its executive committee would quit the organization following the achievement of transactions with GlaxoSmithKline and Eli Lilly to divest three units.
Novartis AG (ADR)(NYSE:NVS) Drug Signifor LAR To Be Used For Treating ...
WallStreetPR - Sep 29, 2014
Boston, MA 09/29/2014 (wallstreetpr) - According to reports, Novartis AG (ADR)(NYSE:NVS)'s drug Signifor LAR has got the recommendation of CHMP for the approval of EU.
Sizzling news - Novartis AG (ADR) (NYSE:NVS), Royal Dutch Shell plc (NYSE ...
Techsonian (press release) - Sep 30, 2014
Manhattan, NY- September 30, 2014 - (Techsonian) - Novartis AG (ADR) (NYSE:NVS)offers patented prescription medicines in a variety of therapeutic areas, including oncology; most important care and established medicines; specialty care, such as ...
Pharma Stocks Alert: Bristol-Myers Squibb Co (NYSE:BMY), Novartis AG (ADR ...
Equities Focus (registration) - Oct 6, 2014
Global biopharmaceutical company Bristol-Myers Squibb Co (NYSE:BMY) said Monday that it has partnered with Novartis AG (ADR) (NYSE:NVS) to conduct a clinical trial evaluating the safety, tolerability and preliminary efficacy of combining BMY's ...